Nilotinib Pharos

Nilotinib, the active ingredient in Nilotinib Pharos, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia in adult patients, covering the chronic, accelerated and blast phases of the disease.

GNH USA supplies Nilotinib Pharos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product meets European Union quality standards and is manufactured under strict Good Manufacturing Practice guidelines, ensuring consistent potency and safety.

Nilotinib is indicated for chronic myeloid leukemia, a malignancy driven by BCR‑ABL tyrosine‑kinase activity. - Chronic myeloid leukemia – chronic phase: achieves hematologic and cytogenetic responses, reducing disease burden and improving survival. - Chronic myeloid leukemia – accelerated phase: helps control disease progression and extends progression‑free survival. - Chronic myeloid leukemia – blast phase: provides targeted inhibition of leukemic cells, often used in combination with other therapies to achieve remission.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Severe hepatic injury: jaundice and markedly elevated transaminases. - Neutropenia: marked reduction in white blood cells increasing infection risk.

When prescribing nilotinib, clinicians should observe several safety measures to minimize risks. - Cardiac monitoring: obtain baseline ECG and periodically assess QT interval. - Hepatic function: evaluate liver enzymes before initiation and during treatment. - Electrolyte balance: correct hypokalemia, hypomagnesemia, and hypocalcemia to reduce QT risk. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or QT‑prolonging agents. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Nilotinib interacts with several medicines; understanding the level of interaction guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase nilotinib exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): additive risk of cardiac arrhythmias. - Antacids containing aluminum or magnesium: reduce nilotinib absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may decrease nilotinib plasma levels. - Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure, monitor for myopathy. - Diuretics that affect electrolytes: monitor potassium and magnesium to prevent QT prolongation.